A team from Erasmus Medical Centre in Rotterdam, the Netherlands, found levels of the protein clusterin were linked to the prevalence and severity of Alzheimer's disease. But it found no link with the development of Alzheimer's, suggesting it is not a useful target for detecting risk.
Researchers analysed baseline plasma levels of clusterin in 60 patients with Alzheimer's disease and a control group of 926 patients. These patients, and a further 156 patients diagnosed with Alzheimer's during the follow-up, were measured again after 7.2 years.
The likelihood of developing Alzheimer's disease increased by 63 per cent for each standard deviation increase in plasma clusterin level.
Visit JAMA for more Alzheimer's articles